Senores Pharmaceuticals Chart
Senores Pharmaceuticals Share Key Metrics
Volume
2.41 L
Market Cap
4296.34 CR
LTQ@LTP
55@932.90
ATP
944.97
Var Margin
18.8 %
Circuit Range
746.35-1119.45
Delivery %
40.27 %
Value
22.73 CR
ASM/GSM
No
Market Lot
1
Summary
Senores Pharmaceuticals Fundamentals
View MoreP/E Ratio
43.56
P/B Ratio
5.22
Div. Yield
0
Sector P/E
68.8
Sector P/B
3.58
Sec. Div. Yield
0.56
Senores Pharmaceuticals Resistance and Support
Pivot 941.35
Resistance
First Resistance
957.7
Second Resistance
982.5
Third Resistance
998.85
Support
First Support
916.55
Second Support
900.2
Third Support
875.4
Senores Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-05-14 | Audited Results |
| 2026-01-20 | Quarterly Results & Others |
| 2026-01-07 | Others |
| 2025-11-06 | Quarterly Results |
| 2025-07-23 | Quarterly Results & Others |
| 2025-05-15 | Audited Results |
| 2025-01-23 | Quarterly Results & Others |
Senores Pharmaceuticals News
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters
Senores Pharmaceuticals board is scheduled to meet on May 14, 2026. The primary agenda is to consider and approve the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.
May 08 2026 17:05:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals promoters and promoter group confirmed no new encumbrances on company shares during the financial year ended March 31, 2026. This annual disclosure ensures compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Apr 22 2026 17:04:00
About Senores Pharmaceuticals
NSE : 28888
BSE : 544319
ISIN : INE0RB801010
Our Company was originally incorporated as “Senores Pharmaceuticals Private Limited” a private limited company under the Companies Act 2013 through certificate of incorporation dated December 26 2017 issued by the Registrar of Companies Central Registration Centre.The name of the Company was thereafter changed to “Senores Pharmaceuticals Limited” upon conversion to a public limited company pursuant to a Board resolution dated August 1 2023 a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24 2023 and the approval of the central government dated September 4 2023 and consequently a fresh certificate of incorporation dated September 4 2023 was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022- Started the domestic business with a launch of the critical care injectables2023- Acquired majority stake in Havix. making it a Subsidiary of our Company- Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited making a Subsidiary of our Company.2024- Launched first CMO product in the US with Jubilant Cadista
Senores Pharmaceuticals Management
| Name | Position |
|---|---|
| Vinay Kumar Mishra | Company Secretary & Compliance Officer |
| Swapnil Jatinbhai Shah | Managing Director |
Senores Pharmaceuticals Similar Stocks
Suven Life Sciences Ltd.
216.38
0.00 (0.00%)
Nephrocare Health Services Ltd.
573.20
0.00 (0.00%)
Supriya Lifescience Ltd.
675.80
0.00 (0.00%)
Innova Captab Ltd.
871.85
0.00 (0.00%)
Artemis Medicare Services Ltd.
270.68
0.00 (0.00%)
Advanced Enzyme Technologies Ltd.
369.80
0.00 (0.00%)
RPG Life Sciences Ltd.
2311.10
0.00 (0.00%)
SMS Pharmaceuticals Ltd.
402.00
0.00 (0.00%)
Indraprastha Medical Corporation Ltd.
415.85
0.00 (0.00%)
Orchid Pharma Ltd.
708.65
0.00 (0.00%)
Senores Pharmaceuticals FAQs
